中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
8期
29-31
,共3页
双J管%并发症%泌尿系%结石
雙J管%併髮癥%泌尿繫%結石
쌍J관%병발증%비뇨계%결석
Double J tube%Complications%Urinary system%Calculi
目的:探讨双J管在泌尿系结石术中的应用,分析双J管置入的并发症原因。方法对该院2011年1月-2013年6月306例上尿路结石手术留置双J管患者按手术方式分为3组,对临床资料进行回顾性分析。结果306例双J管内引流所致的并发症主要有6种,共62例(20.26%),包括泌尿系感染(31例,50.00%)、肉眼血尿(16例,20.97%)、位置异常(11例,11.29%)、返流(6例,9.68%)、附壁结石(3例,4.84%)、双J管断裂(1例,1.61%),分别给予了对症处理。结论泌尿系结石手术中留置双J管出现的并发症通过积极治疗可避免或减轻。
目的:探討雙J管在泌尿繫結石術中的應用,分析雙J管置入的併髮癥原因。方法對該院2011年1月-2013年6月306例上尿路結石手術留置雙J管患者按手術方式分為3組,對臨床資料進行迴顧性分析。結果306例雙J管內引流所緻的併髮癥主要有6種,共62例(20.26%),包括泌尿繫感染(31例,50.00%)、肉眼血尿(16例,20.97%)、位置異常(11例,11.29%)、返流(6例,9.68%)、附壁結石(3例,4.84%)、雙J管斷裂(1例,1.61%),分彆給予瞭對癥處理。結論泌尿繫結石手術中留置雙J管齣現的併髮癥通過積極治療可避免或減輕。
목적:탐토쌍J관재비뇨계결석술중적응용,분석쌍J관치입적병발증원인。방법대해원2011년1월-2013년6월306례상뇨로결석수술류치쌍J관환자안수술방식분위3조,대림상자료진행회고성분석。결과306례쌍J관내인류소치적병발증주요유6충,공62례(20.26%),포괄비뇨계감염(31례,50.00%)、육안혈뇨(16례,20.97%)、위치이상(11례,11.29%)、반류(6례,9.68%)、부벽결석(3례,4.84%)、쌍J관단렬(1례,1.61%),분별급여료대증처리。결론비뇨계결석수술중류치쌍J관출현적병발증통과적겁치료가피면혹감경。
Objective To explore the use of double J tube in the operation of calculi in urinary system, and analyze the causes of complications after retention of double J stent in upper urinary tract operations. Methods We studied the clinical data of 306 cases admitted in our hospital from January, 2011 to June, 2013, all the patients received upper urinary tract stone surgery with the use of double J tube, and they were divided into three groups according to the surgical approach. Results The study showed that, of the 306 cases, there were 6 kinds of complications, a total of 62 cases(20.26%), caused by double J tube drainage, including urinary infection (31 cases, 50.00%); gross hematuria (16 cases, 20.97%); malposition of double J tube (11 cases, 11.29%); backstreaming (6 cases, 9.68%); crystal stone in the double J tube surface(3 cases, 4.84%);fracture of double J tube(1 case,1.61%), all extended individual treatment. Conclusion Complications can be avoided or mitigated by aggressive treatment after the urinary calculi surgery indwelling double J tube.